Organs-on-chips Market - Type [Product (Liver, Lung, Heart, Kidney), Service], Material (PDMS, Polymer, Glass), Model Type (Single, Multi-organ), Application (Drug Discovery, Toxicity Testing, Personalized Medicine), End-user, Global Forecast 2024 – 2032

Organs-on-chips Market Size

Organs-on-chips Market size was valued at USD 116.5 million in 2023 and is expected to record over USD 1.4 billion by 2032 driven by the increasing demand for more accurate and reliable in-vitro models of human organs for drug discovery, toxicity testing, and disease modelling.
 

Organs-on-chips are microfluidic devices that hold the potential to revolutionize the pharmaceutical and healthcare industries by providing more physiologically relevant R&D platforms. Moreover, this technology offers a significant benefit for potentially minimizing the need for animals in medical research, aligning with ethical practices. For instance, the Humane Society International stated that over 115 million animals are utilized for clinical testing worldwide. The strong ability to replicate human organs affordably also makes these devices promising tools in non-animal alternative testing for drug discovery.
 

However, the high cost of developing and manufacturing sophisticated devices can be a major barrier, limiting the product adoption in well-funded research institutes and large pharmaceutical companies. Regulatory challenges are also a major obstacle, as certification and approval processes for new technologies are lengthy and rigorous. Limited awareness and acceptance among the general scientific and medical communities will further hinder the market expansion.
 

Organs-on-chips Market Trends

The rising prevalence of chronic diseases is increasing the need for rapid drug discovery methods, driving the necessity for drug toxicity identification, technological progress, and the introduction of new products by major market players. For instance, Emulate Inc.'s alveolus lung-chip and airway lung-chip models, helped in COVID-19 research. These innovative organ-on-chip technologies supported in enhancing the early infectious disease clinical studies for expediting the pandemic research efforts. 
 

The growing advancement and the support by regulatory authorities are accelerating the development and adoption of advanced organ-on-chip technologies. For instance, in January 2023, FDA Modernization Act 2.0 approval aimed to accelerate the organ-on-chip integration in pharmaceuticals, using innovations in testing methods for ethical and streamlined drug development. Advanced technologies are providing an opportunity for the pharmaceutical industry to expedite drug development while reducing reliance on animal studies.  
 

Organs-on-chips Market Analysis

Based on type, the market size from the product segment is expected to generate a revenue of USD 944.7 million by 2032. The precise prediction of airborne nanoparticle absorption and accurate replication of the inflammatory response to microbial pathogens has stirred the widespread adoption of lung-on-chip models. The prevalence of pulmonary diseases, especially tuberculosis, has surged the demand for effective disease management, contributing to segment growth. According to the Center for Disease Control and Prevention (CDC), two billion people, accounting for one-fourth of the world’s population, get infected with tuberculosis (TB)annually.

Based on material, the organs-on-chips market from the polydimethylsiloxane (PDMS) segment is expected to record USD 646.9 million by 2032. Microfluidic organ-on-chip platform using PDMS has gained rapid popularity and widespread acceptance due to its compatibility with high-resolution microstructures and nanostructures through replica molding. PDMS is also recognized for its biocompatibility, optical transparency, and gas permeability, making it well-suited for biological applications.  
 

Based on model type, the single-organ model segment is anticipated to generate USD 881.5 million by 2032 attributed to their specificity and focused applications. The single-organ model maintains the ability to replace organ-level responses in a controlled environment, leading to widespread product adoption.
 

Based on application, the organs-on-chips market from the drug discovery segment will exhibit over 32% CAGR through 2032. The trials in novel drug discovery, characterized by rising R&D costs and low success rate in clinical trials is propelling the demand for advanced and precise predictive preclinical in-vitro models. 
 

Based on end-user, the organs-on-chips market value from the pharmaceutical and biotechnology companies segment reached USD 73.3 million in 2023. Several pharmaceutical and biotechnology companies are actively seeking innovative solutions to bridge the translational gap between preclinical and clinical drug development to reduce attrition rates. Substantial investments are helping them to prioritize R&D while focusing on personalized medicine, and consistently launching new products. Strong emphasis on enhancing preclinical testing efficiency will drive the segment growth. 
 

North America organs-on-chips market size was USD 44.9 million in 2023 and is anticipated to generate USD 533.9 million by 2032 attributed to the rising prevalence of chronic diseases. For instance, in June 2023, the FDA granted a partial option award to further propel the development of organ chips for radiation countermeasure research, evaluating efficacy and screening experimental compounds for Medical Countermeasures (MCM).  Furthermore, the growing investments by the public and private institutes, exemplified by the National Institutes of Health (NIH) funding for biotechnology will signify continuous regional growth.
 

Organs-on-chips Market Share

Leading organs-on-chips industry players are focusing on R&D, product innovation, and strategic collaborations to gain a competitive edge and meet the growing demand for advanced in-vitro models. These firms are also eyeing investments to proliferate their portfolio.
 

Organs-on-chips Market Companies

Prominent participants operating in the organs-on-chips industry are:

• Altis Biosystems
• AlveoliX AG
• Axosim
• Bi/ond Solutions B.V
• Cherry Biotech
• CN-Bio
• Emulate, Inc.
• Hesperos, Inc.
• Insphero
• MesoBioTech
• Mimetas B.V.
• Nortis Inc.
• React4Life
• TARA Biosystems (Valo Health)
• TissUse GmbH
   

Organs-on-chips Industry News:

• In September 2023, NETRI unveiled an innovative series of organ-on-chip kits for efficient in-vitro modelling for the peripheral nervous system. These devices were intricately designed to accommodate cells from diverse species. 
   
• In June 2023, Emulate, Inc. introduced its Chip-A1 Accessible Chip via an early access program. This chip enabled the efficient modelling of intricate 3D tissues like the tumor microenvironment and skin, with direct compound dosing capabilities.
   

The organ on chip market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Type

• Product
  • Liver-on-chip
  • Lung-on-chip
  • Heart-on-chip
  • Kidney-on-chip
  • Other products
• Service

Market, By Material

• Polydimethylsiloxane (PDMS)
• Polymer
• Glass

Market, By Model Type

• Single-organ model
• Multi-organ model

Market, By Application

• Drug discovery
• Toxicity testing
• Disease modeling
• Personalized medicine
• Other applications

Market, By End-user

• Pharmaceutical and biotechnology companies
• Academic and research institutes
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East and Africa